Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

iKang Healthcare Completes $153 Million US IPO

publication date: Apr 11, 2014
iKang Guobin Healthcare completed its IPO on the NASDAQ exchange, pricing 10.9 million shares at $14, the high side of its $12-$14 range. The offering raised $153 million and values the company at $903 million. Selling shareholders offered 31% of the shares, rendering iKang’s share of the proceeds $95 million after commissions. iKang’s 42 company-owned diagnostic/preventative clinics are located in China’s 13 largest cities. More details....

Stock Symbol: (NSDQ: KANG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital